160 related articles for article (PubMed ID: 33082884)
1. Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication.
Kang Q; Chen J; Luo H; Tan N; Gao H; Zhang X; Yu M; Liu D; Xi H; An Y; Han Y; Cheng R; Xu X
Dis Markers; 2020; 2020():8539804. PubMed ID: 33082884
[TBL] [Abstract][Full Text] [Related]
2. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of novel hepatic fibrosis markers in assessing cirrhosis in patients with chronic hepatitis C].
Kang Q; Liu JX; Tan N; Chen HY; Pan JL; Han YF; Xu XY
Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):56-64. PubMed ID: 36948850
[No Abstract] [Full Text] [Related]
4. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
5. Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China.
Jin X; Fu B; Wu ZJ; Zheng XQ; Hu JH; Jin LF; Tang LL
Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):384-389. PubMed ID: 32540209
[TBL] [Abstract][Full Text] [Related]
6. Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
Kawagishi N; Suda G; Kimura M; Maehara O; Yamada R; Tokuchi Y; Kubo A; Kitagataya T; Shigesawa T; Suzuki K; Ohara M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Sakamoto N
Sci Rep; 2021 Apr; 11(1):9207. PubMed ID: 33911145
[TBL] [Abstract][Full Text] [Related]
7. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
Gaeta GB; Aghemo A; Menzaghi B; D'Offizi G; Giorgini A; Hasson H; Brancaccio G; Palma M; Termini R;
Medicine (Baltimore); 2018 Jul; 97(27):e11307. PubMed ID: 29979400
[TBL] [Abstract][Full Text] [Related]
10. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
[TBL] [Abstract][Full Text] [Related]
11. Chitinase 3-like-1, Tolloid-like protein 1, and intergenic gene polymorphisms are predictors for hepatocellular carcinoma development after hepatitis C virus eradication by direct-acting antivirals.
Mangoud NOM; Ali SA; El Kassas M; Soror SH
IUBMB Life; 2021 Feb; 73(2):474-482. PubMed ID: 33347699
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases.
Jiang Z; Wang S; Jin J; Ying S; Chen Z; Zhu D; Xiao B; Hu Y; Qian Y; Cai T; Fu L
J Clin Lab Anal; 2020 May; 34(5):e23200. PubMed ID: 31916309
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
14. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
15. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia.
Butsashvili M; Gvinjilia L; Kamkamidze G; Metreveli D; Dvali S; Rukhadze T; Gamkrelidze A; Nasrullah M; Shadaker S; Morgan J; Averhoff F
BMC Res Notes; 2020 Jul; 13(1):332. PubMed ID: 32653020
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
Abd Alla MDA; El Awady MK; Dawood RM; Elhawary MA; Al-Azhari SS; Galal AGM
Arch Virol; 2018 Oct; 163(10):2765-2774. PubMed ID: 29971486
[TBL] [Abstract][Full Text] [Related]
18. The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir.
Wu CK; Chen LW; Chang TS; Tung SY; Lin CY; Hung CH; Lu SN; Lin CL; Chen CH; Hsu CW; Hu TH; Sheen IS
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215955
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
[TBL] [Abstract][Full Text] [Related]
20. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.
Rockey DC; Friedman SL
Gastroenterology; 2021 Apr; 160(5):1502-1520.e1. PubMed ID: 33529675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
